2024
Impact of early intervention on health status outcomes in peripheral artery disease patients with chronic total occlusion lesions using the PORTRAIT registry
Cerrud-Rodriguez R, Romain G, Hussain Y, Cleman J, Callegari S, Scierka L, Smolderen K, Mena-Hurtado C. Impact of early intervention on health status outcomes in peripheral artery disease patients with chronic total occlusion lesions using the PORTRAIT registry. Journal Of Vascular Surgery 2024, 80: 780-790.e10. PMID: 38735596, DOI: 10.1016/j.jvs.2024.04.061.Peer-Reviewed Original ResearchPeripheral Artery QuestionnairePeripheral arterial diseaseHealth statusChronic total occlusionChronic total occlusion lesionsPAD-specific health statusEarly invasive treatmentMultilevel generalized linear regression modelsPeripheral arterial disease symptomsLower extremity peripheral arterial diseaseBaseline health statusHealth status outcomesInvasive treatmentHealth status trajectoriesNon-invasive treatmentPatients' health statusImpact of early interventionHigh health statusFollow-upPeripheral arterial disease patientsSymptomatic peripheral arterial diseaseMonths of follow-upPresence of chronic total occlusionNon-invasive treatment strategyStatus outcomesAn Interventional Radiologist's Guide to Lung Cancer
Fish A, Madoff D. An Interventional Radiologist's Guide to Lung Cancer. Seminars In Interventional Radiology 2024, 41: 121-128. PMID: 38993601, PMCID: PMC11236454, DOI: 10.1055/s-0044-1786725.Peer-Reviewed Original ResearchLung cancer patientsLung cancerTissue diagnosisInterventional radiologistsCancer patientsField of interventional oncologyTreating lung cancer patientsTreatment of lung cancerEarly-stage diseaseAdvanced medical therapiesLung cancer complicationsBiopsy complicationsRadiation therapyPercutaneous ablationSurgical therapyMedical therapyInterventional oncologyEndovascular therapyInvasive treatmentCancer complicationsCancer deathTherapyGold standardCancerTreatment pathways
2022
One-Year Health Status Outcomes Following Early Invasive and Noninvasive Treatment in Symptomatic Peripheral Artery Disease
Angraal S, Hejjaji V, Tang Y, Gosch KL, Patel MR, Heyligers J, White CJ, Nolthenius R, Mena-Hurtado C, Aronow HD, Moneta GL, Fitridge R, Soukas PA, Abbott JD, Secemsky EA, Spertus JA, Smolderen KG. One-Year Health Status Outcomes Following Early Invasive and Noninvasive Treatment in Symptomatic Peripheral Artery Disease. Circulation Cardiovascular Interventions 2022, 15: e011506. PMID: 35579010, PMCID: PMC11299756, DOI: 10.1161/circinterventions.121.011506.Peer-Reviewed Original ResearchConceptsHealth status outcomesPropensity-matched sampleEarly invasiveHealth statusEarly revascularizationStatus outcomesSymptomatic peripheral artery diseaseDisease-specific health statusNoninvasive management strategiesPeripheral Artery QuestionnaireTreatment-resistant symptomsEarly invasive managementPeripheral artery diseaseBaseline health statusEarly invasive treatmentHealth status trajectoriesHealth status improvementReal-world evidencePORTRAIT registryArtery diseaseInvasive managementNoninvasive managementPatient preferencesInvasive treatmentLifestyle changesMinimally Invasive Endoscopic and Surgical Management of Rectal Neoplasia
Al Ghamdi S, Leeds I, Fang S, Ngamruengphong S. Minimally Invasive Endoscopic and Surgical Management of Rectal Neoplasia. Cancers 2022, 14: 948. PMID: 35205695, PMCID: PMC8869910, DOI: 10.3390/cancers14040948.Peer-Reviewed Original ResearchRectal neoplasiaRectal cancerImproved survival outcomesLocal recurrence rateAppropriate treatment modalitySurgical management optionsColorectal cancer casesCharacteristic natural historyInvasive endoscopicSurgical managementRecurrence rateSurvival outcomesClinical burdenTreatment modalitiesInvasive treatmentCancer casesWorldwide burdenInterventional endoscopyNatural historyNeoplasiaSuccessful managementEarly detectionCancerOne-thirdMultidisciplinary effortChapter 30 The “nitinol-constrained” Chocolate balloon angioplasty: clinical applications in patients with severe atherosclerotic peripheral arterial disease
Binyamin G, Gaston S, Konstantino E, Konstantino M, Lansky A. Chapter 30 The “nitinol-constrained” Chocolate balloon angioplasty: clinical applications in patients with severe atherosclerotic peripheral arterial disease. 2022, 673-688. DOI: 10.1016/b978-0-12-821451-0.00006-9.Peer-Reviewed Original ResearchPeripheral arterial diseaseAtherosclerotic peripheral arterial diseaseArterial diseaseBalloon angioplastyRevascularization strategyImpaired perfusionClinical syndromeBalloon catheterInvasive treatmentAngioplastyAngioplasty devicesDiseaseClinical applicationStentingPatientsCatheterSyndromePerfusionMainstay
2021
Minimally invasive treatment of abdominal lymphocele: A review of contemporary options and how to approach them.
Khorshidi F, Majdalany B, Peters G, Tran A, Shaikh J, Liddell R, Perez Lozada J, Kokabi N, Nezami N. Minimally invasive treatment of abdominal lymphocele: A review of contemporary options and how to approach them. Lymphology 2021, 54: 56-67. PMID: 34735751, DOI: 10.2458/lymph.4727.Peer-Reviewed Original ResearchConceptsTreatment optionsInvasive treatment optionLower limb edemaGold standard treatmentAdjacent structuresVital adjacent structuresMost lymphocelesRenal transplantCatheter drainageSymptomatic lymphoceleLymphatic embolizationPercutaneous treatmentPercutaneous aspirationRetroperitoneal surgeryGynecologic surgeryStandard treatmentLimb edemaInvasive treatmentLymphoceleFluid collectionSurgeryVessel disruptionFunctional compromiseInterventional technologiesMass effect
2020
Physical Activity After Treatment for Symptomatic Peripheral Artery Disease
Peri-Okonny PA, Patel S, Spertus JA, Jackson EA, Malik AO, Provance J, Mena-Hurtado C, Shishehbor MH, Hijjaji V, Gosch KL, Smolderen K. Physical Activity After Treatment for Symptomatic Peripheral Artery Disease. The American Journal Of Cardiology 2020, 138: 107-113. PMID: 33065083, PMCID: PMC7736254, DOI: 10.1016/j.amjcard.2020.10.011.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnkle Brachial IndexConservative TreatmentEndovascular ProceduresExerciseExercise TherapyFemaleHealth StatusHumansHydroxymethylglutaryl-CoA Reductase InhibitorsIntermittent ClaudicationLeisure ActivitiesLinear ModelsLogistic ModelsMaleMiddle AgedMultivariate AnalysisPatient SatisfactionPeripheral Arterial DiseasePlatelet Aggregation InhibitorsQuality of LifeSedentary BehaviorSmoking CessationSocial InteractionVascular Surgical ProceduresWorkConceptsPhysical activity levelsPhysical activityInvasive treatmentSymptomatic peripheral artery diseasePeripheral artery diseaseMultivariable logistic regressionAssociation of treatmentActivity levelsMultivariable linear regressionHealth status changesHealth status gainsPAD outcomesArtery diseaseVascular clinicInvasive groupNoninvasive treatmentHealth statusLogistic regressionActivity statusLTPAClaudicationTreatmentPatientsStatus changesAssociationFactors Associated With Receipt of Partial Nephrectomy or Minimally Invasive Surgery for Patients With Clinical T1a and T1b Renal Masses: Implications for Regionalization of Care
Sterling J, Rivera-Núñez Z, Patel HV, Farber NJ, Kim S, Radadia KD, Modi PK, Goyal S, Parikh R, Weiss RE, Kim IY, Elsamra SE, Jang TL, Singer EA. Factors Associated With Receipt of Partial Nephrectomy or Minimally Invasive Surgery for Patients With Clinical T1a and T1b Renal Masses: Implications for Regionalization of Care. Clinical Genitourinary Cancer 2020, 18: e643-e650. PMID: 32389458, PMCID: PMC7502425, DOI: 10.1016/j.clgc.2020.03.011.Peer-Reviewed Original ResearchConceptsNational Cancer Data BaseRenal cell carcinomaPartial nephrectomyClinical T1 renal cell carcinomaT1 renal cell carcinomaInvasive surgeryUtilization of MISRegionalization of careLower socioeconomic groupsT1b renal massesClinical T1aCT1a patientsCT1a tumorsCT1b patientsCT1b tumorsRCC surgeryTreatment disparitiesCell carcinomaPatient populationRenal massesInvasive treatmentPatientsAcademic centersLogistic regressionPrivate insurance
2019
LEISURE TIME PHYSICAL ACTIVITY AFTER INVASIVE TREATMENT FOR SYMPTOMATIC PERIPHERAL ARTERY DISEASE: INSIGHTS FROM THE PORTRAIT REGISTRY
Peri-Okonny P, Malik A, Provance J, Hijjaji V, Gosch K, Spertus J, Smolderen K. LEISURE TIME PHYSICAL ACTIVITY AFTER INVASIVE TREATMENT FOR SYMPTOMATIC PERIPHERAL ARTERY DISEASE: INSIGHTS FROM THE PORTRAIT REGISTRY. Journal Of The American College Of Cardiology 2019, 73: 2093. DOI: 10.1016/s0735-1097(19)32699-3.Peer-Reviewed Original Research
2017
Mechanochemical Ablation of Superficial Veins
Aurshina A, Ochoa Chaar C. Mechanochemical Ablation of Superficial Veins. 2017, 133-143. DOI: 10.1007/978-3-319-65226-9_10.Peer-Reviewed Original ResearchMechanochemical ablationTraditional surgical ligationEquivalent clinical efficacyEndovenous thermal ablationNonthermal ablative techniquesSurgical ligationVenous insufficiencyClinical efficacySaphenous veinAblative techniquesInvasive treatmentSuperficial veinsTumescent anesthesiaLess discomfortThermal ablationAblationVeinPreinfarct Health Status and the Use of Early Invasive Versus Ischemia-Guided Management in Non–ST-Elevation Acute Coronary Syndrome
Qintar M, Smolderen KG, Chan PS, Gosch KL, Jones PG, Buchanan DM, Girotra S, Spertus JA. Preinfarct Health Status and the Use of Early Invasive Versus Ischemia-Guided Management in Non–ST-Elevation Acute Coronary Syndrome. The American Journal Of Cardiology 2017, 120: 1062-1069. PMID: 28797471, PMCID: PMC5766265, DOI: 10.1016/j.amjcard.2017.06.045.Peer-Reviewed Original ResearchConceptsEarly invasive managementEarly invasive treatmentInvasive managementHealth statusMyocardial infarctionInvasive treatmentAcute Myocardial Infarction Patients' Health StatusAcute Coronary Events (GRACE) risk scoreElevation acute coronary syndromeProspective Registry Evaluating OutcomesHighest risk decileHospital treatment strategiesPoor baseline qualityAcute coronary syndromeElevation myocardial infarctionWorse health statusHigher mortality riskPatients' health statusQuality of lifeAngina frequencyNSTEMI cohortCoronary syndromeGRACE scoreMulticenter registryNon–ST
2016
Irreversible Electroporation in Interventional Oncology: Where We Stand and Where We Go
Savic LJ, Chapiro J, Hamm B, Gebauer B, Collettini F. Irreversible Electroporation in Interventional Oncology: Where We Stand and Where We Go. RöFo 2016, 188: 735-745. PMID: 27074423, DOI: 10.1055/s-0042-104203.Peer-Reviewed Original ResearchConceptsClinical evidenceIrreversible electroporationInterventional oncologyPancreatic irreversible electroporationSite-specific complicationsAvailable clinical evidenceUse of IRELimited clinical evidenceFavorable safety profileTolerable morbidityOncologic efficacyPreclinical findingsBile ductSafety profileNeurovascular bundleInvasive treatmentLung parenchymaAblation therapySolid tumorsClinical settingTumor ablation therapyHeat sink effectNon-thermal fashionLiverTumor ablation
2015
One Year Health Status Benefits Following Treatment for New Onset or Exacerbation of Peripheral Arterial Disease Symptoms: The Importance of Patients' Baseline Health Status
van Zitteren M, Denollet J, Heyligers JM, Elshof JW, Nooren MJ, Burger DH, de Fijter WM, Vriens PW, Smolderen KG. One Year Health Status Benefits Following Treatment for New Onset or Exacerbation of Peripheral Arterial Disease Symptoms: The Importance of Patients' Baseline Health Status. European Journal Of Vascular And Endovascular Surgery 2015, 50: 213-222. PMID: 26036809, DOI: 10.1016/j.ejvs.2015.04.003.Peer-Reviewed Original ResearchMeSH KeywordsAgedDisease ProgressionFemaleHealth StatusHealth Status IndicatorsHumansLinear ModelsMaleMental HealthMiddle AgedNetherlandsPeripheral Arterial DiseasePredictive Value of TestsPropensity ScoreProspective StudiesRecovery of FunctionRisk FactorsSeverity of Illness IndexTime FactorsTreatment OutcomeUltrasonography, Doppler, DuplexConceptsHealth status scoresPeripheral arterial diseaseHealth status gainsBaseline health statusInvasive treatmentStatus scoreHealth statusPatient's baseline health statusPeripheral arterial disease symptomsHealth status levelsHealth status outcomesNew onsetPAD symptomsVascular clinicArterial diseaseHighest quartilePCS scoresInvasive strategyTreatment strategiesClinical informationStatus outcomesPatientsLinear regression analysisChange scoresExacerbation
2014
Determinants of invasive treatment in lower extremity peripheral arterial disease
van Zitteren M, Vriens PW, Burger DH, de Fijter WM, Gerritsen GP, Heyligers JM, Nooren MJ, Smolderen KG. Determinants of invasive treatment in lower extremity peripheral arterial disease. Journal Of Vascular Surgery 2014, 59: 400-408.e2. PMID: 24461863, DOI: 10.1016/j.jvs.2013.08.045.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAnkle Brachial IndexChi-Square DistributionDecision Support TechniquesEndovascular ProceduresFemaleHealth StatusHumansLower ExtremityMaleMiddle AgedNetherlandsOdds RatioPatient SelectionPeripheral Arterial DiseasePredictive Value of TestsProspective StudiesReferral and ConsultationRisk FactorsTreatment OutcomeUltrasonography, Doppler, DuplexVascular Surgical ProceduresConceptsPeripheral arterial diseaseLower extremity peripheral arterial diseasePhysical component scaleInvasive treatmentLesion locationHealth statusArterial diseaseTreatment referralSymptomatic lower extremity peripheral arterial diseaseProspective observational cohort studyVascular surgery outpatient clinicProximal lesion locationAnkle-brachial indexObservational cohort studySurgery outpatient clinicShort Form-12Poor health statusPatients' health statusPoisson regression analysisPAD diagnosisCohort studyPAD symptomsIndependent predictorsAmbulatory patientsForm-12
2013
Evaluation of YO-PRO-1 as an early marker of apoptosis following radiofrequency ablation of colon cancer liver metastases
Fujisawa S, Romin Y, Barlas A, Petrovic L, Turkekul M, Fan N, Xu K, Garcia A, Monette S, Klimstra D, Erinjeri J, Solomon S, Manova-Todorova K, Sofocleous C. Evaluation of YO-PRO-1 as an early marker of apoptosis following radiofrequency ablation of colon cancer liver metastases. Cytotechnology 2013, 66: 259-273. PMID: 24065619, PMCID: PMC3918265, DOI: 10.1007/s10616-013-9565-3.Peer-Reviewed Original ResearchColorectal-cancer liver metastasesYO-PRO-1Liver metastasesColon cancer liver metastasisLiver tissuePropidium iodineCancer liver metastasesMouse liverMarkers of cell deathMinimally invasive treatmentMouse liver parenchymaSurrounding liver tissueMarkers of apoptosisSurgical resectionPlasma membrane injuryRadiofrequency ablationDynamic CTPI signalingNonsurgical patientsPathological examinationTarget tumorsInvasive treatmentPositive cellsBiopsy samplesNormal mouse liver
2007
Acute Coronary Care in the Elderly, Part II
Alexander KP, Newby LK, Armstrong PW, Cannon CP, Gibler WB, Rich MW, Van de Werf F, White HD, Weaver WD, Naylor MD, Gore JM, Krumholz HM, Ohman EM. Acute Coronary Care in the Elderly, Part II. Circulation 2007, 115: 2570-2589. PMID: 17502591, DOI: 10.1161/circulationaha.107.182616.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAge FactorsAgedAged, 80 and overAngina, UnstableAngioplasty, Balloon, CoronaryCardiovascular AgentsClinical Trials as TopicCombined Modality TherapyDisease ManagementDisease SusceptibilityEvidence-Based MedicineFemaleFibrinolytic AgentsGeriatricsHumansMaleMiddle AgedMulticenter Studies as TopicMyocardial InfarctionMyocardial RevascularizationPatient RightsPractice Guidelines as TopicPrejudiceQuality of LifeRegistriesRisk FactorsStentsThrombolytic TherapyTreatment OutcomeConceptsST-segment elevation myocardial infarctionElderly patientsMyocardial infarctionInvasive treatmentAmerican Heart Association scientific statementOlder adultsComplex health statusGuideline-recommended careTreatment-associated risksAcute coronary syndromeAcute coronary careTreatment-related benefitsAge 85 yearsPatient-centered mannerQuality of lifeLimited trial dataCoronary syndromeReperfusion strategyAbsolute contraindicationAdjunctive therapyCardiovascular medicationsOlder patientsCoronary careGeriatric conditionsElderly subgroupAcute Coronary Care in the Elderly, Part I
Alexander KP, Newby LK, Cannon CP, Armstrong PW, Gibler WB, Rich MW, Van de Werf F, White HD, Weaver WD, Naylor MD, Gore JM, Krumholz HM, Ohman EM. Acute Coronary Care in the Elderly, Part I. Circulation 2007, 115: 2549-2569. PMID: 17502590, DOI: 10.1161/circulationaha.107.182615.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAge FactorsAgedAged, 80 and overAngina, UnstableAngioplasty, Balloon, CoronaryAnticoagulantsCardiac CatheterizationClinical Trials as TopicComorbidityCreatinineDisease ManagementDisease SusceptibilityDose-Response Relationship, DrugEvidence-Based MedicineFemaleHospital MortalityHumansKidneyLife ExpectancyMaleMetabolic Clearance RateMulticenter Studies as TopicMyocardial InfarctionPlatelet Aggregation InhibitorsPractice Guidelines as TopicRegistriesRisk AssessmentRisk FactorsStentsTreatment OutcomeConceptsAcute coronary syndromeElderly patientsOlder patientsInvasive treatmentSegment elevation acute coronary syndromesAmerican Heart Association scientific statementST-segment elevation myocardial infarctionElevation acute coronary syndromeComplex health statusAcute coronary careSubset of patientsAcute cardiac diseaseAge subgroup analysisTreatment-related benefitsGuideline-based careTreatment-related risksOutcomes of importanceQuality of lifeLimited trial dataCommunity practiceBasis of ageApplication of evidenceHigher disease riskGeriatric perspectiveCoronary syndrome
2006
Single-Blind, Multicenter, Placebo Controlled, Parallel Study to Assess the Safety and Efficacy of Intralesional Interferon α-2b for Minimally Invasive Treatment for Peyronie’s Disease
Hellstrom WJ, Kendirci M, Matern R, Cockerham Y, Myers L, Sikka SC, Venable D, Honig S, McCullough A, Hakim LS, Nehra A, Templeton LE, Pryor JL. Single-Blind, Multicenter, Placebo Controlled, Parallel Study to Assess the Safety and Efficacy of Intralesional Interferon α-2b for Minimally Invasive Treatment for Peyronie’s Disease. Journal Of Urology 2006, 176: 394-398. PMID: 16753449, DOI: 10.1016/s0022-5347(06)00517-9.Peer-Reviewed Original ResearchConceptsIntralesional interferon alpha-2bAlpha-2bInterferon alpha-2bPeyronie's diseasePenile curvatureInterferon alpha-2b therapyPlaque sizeAlpha-2b therapyIntralesional interferon αMean International IndexErectile Function scoreFlu-like symptomsBlood flow improvementParallel studyPenile painPlacebo-ControlledPain resolutionConsecutive patientsErectile functionFunction scoresMean ageControl armInternational IndexInvasive treatmentStudy completion
1997
Inhaled Nitric Oxide and Persistent Pulmonary Hypertension of the Newborn
Roberts J, Fineman J, Morin F, Shaul P, Rimar S, Schreiber M, Polin R, Zwass M, Zayek M, Gross I, Heymann M, Zapol W, Thusu K, Zellers T, Wylam M, Zaslavsky A. Inhaled Nitric Oxide and Persistent Pulmonary Hypertension of the Newborn. New England Journal Of Medicine 1997, 336: 605-610. PMID: 9032045, DOI: 10.1056/nejm199702273360902.Peer-Reviewed Original ResearchConceptsPersistent pulmonary hypertensionPulmonary vascular resistanceExtracorporeal membrane oxygenationPulmonary hypertensionSystemic oxygenationNitric oxideSevere hypoxemiaVascular resistanceMembrane oxygenationSystemic arterial hypoxemiaSystemic blood pressureLong-term therapyFull-term infantsNumber of deathsSystemic hypotensionArterial hypoxemiaBlood pressureMulticenter studyConventional therapyAlternative therapiesInvasive treatmentNitric oxide groupHypertensionInitial improvementMethemoglobin levels
1983
The role of protriptyline in obstructive sleep apnea.
Brownell L, Perez-Padilla R, West P, Kryger M. The role of protriptyline in obstructive sleep apnea. Bulletin Européen De Physiopathologie Respiratoire 1983, 19: 621-4. PMID: 6360257.Peer-Reviewed Original ResearchConceptsObstructive sleep apneaSleep apneaTreatment of mildLong-term treatmentTricyclic agentsObese patientsObstructive apneaClinical statusCrossover trialImproved oxygenationInvasive treatmentTerm treatmentPatientsApneaArousal frequencySomnolenceProtriptylineTreatmentTrialsOxygenationREMTherapyMildMonths
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply